NONALCOHOLIC FATTY LIVER DISEASE AND RISK OF INCIDENT HYPERTENSION: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i3.1616Keywords:
Cardiovascular disease, Hypertension, Inflammation, Insulin resistance, Nonalcoholic fatty liver disease (NAFLD)Abstract
NAFL, or Non-Alcoholic Fatty liver, is a disorder characterized by the presence of steatosis; steatosis, an inflammation and expansion of liver cells with or without liver fibrosis (NASH, Non-Alcoholic Steatohepatosis); and cirrhosis. If more fibrosis or cirrhosis develops, the potential risk of liver cancer will grow. Current epidemiological research indicates that around 49.5% of people with hypertension also have NAFLD. In addition, the prevalence of hypertension is significantly higher in patients with NAFLD than in the general population. It has been proven that both the presence of NAFLD and the severity of the illness are significantly associated with higher risks of a broad spectrum of extrahepatic effects, including cardiovascular disease (CVD) and type 2 diabetes mellitus. Hypertension is a disorder characterized by multiple medical issues. In the majority of patients, the pathophysiological cause is unknown (essential or primary). Primary hypertension is incurable but can be managed. Another group with a low percentage has a unique cause, which is known as secondary hypertension. Endogenous and exogenous causes of secondary hypertension are numerous. If the source of secondary hypertension can be discovered, these patients' hypertension may be curable. All studies demonstrate that persons with NAFLD are more likely to have hypertension than those without NAFLD.
References
Cojocariu C, Singeap AM, Girleanu I, Chiriac S, Muzica CM, Sfarti CV, et al. Nonalcoholic Fatty Liver DiseaseRelated Chronic Kidney Disease. Can J Gastroenterol Hepatol. 2020;2020:3–5.
Wong WK, Chan WK. Nonalcoholic Fatty Liver Disease: A Global Perspective. Clin Ther. 2021;43(3):473–99.
Ratziu V, Bellentani S, Pinto-Cortez H, Day C, Giulo M. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53(2):372–84.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol. 2007;22(6):788–93. [7] Fauci AS, Jameson JL, Kasper D, et al. Harrison’s Principles of Internal Medicine 19th Edition. New York: McGraw-Hill Education; 2018.
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA. Guideline for the Prevention, Detection,
Evaluation, and Management of High Blood Pressure in Adults: , “A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:127–248.
Zhou F, Zhou J, Wang W. Zhang XJ, Ji YX, Zhang P, et al. Unexpected rapid increase in the burden of nonalcoholic fatty liver disease in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology. 2019;70:1119– 33.
Zhang X, She Z, Li H. Time to step‐up the fight against NAFLD. Hepatology. 2018;67(6):2068–71.
Cai J, Zhang X, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39(1):328–48.
Bonnet F, Gastaldelli A, Natali A, Roussel R, Petrie J, Tichet J, et al. Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. J Hypertens. 2017;35(3):493–500.
Sung K-C, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol. 2014;60(5):1040–5.
Aneni EC, Oni ET, Martin SS, Blaha MJ, Agatston AS, Feldman T, et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015;33(6):1207–14.
Ryoo J, Suh YJ, Shin HC, Cho YK, Choi J, Park SK. Clinical association between non‐alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol. 2014;29(11):1926–31.
Zhou K, Cen J. Retracted article: the fatty liver index (FLI) and incident hypertension: a longitudinal study among Chinese population. Lipids Health Dis. 2018;17:1–7.
Uchmanowicz I, Chudiak A, Jankowska-Polańska B, et al. Hypertension and Frailty Syndrome in Old Age: Current Perspectives. Card Fail Rev. 2017;3(2):102–7.
Setiati S, Alwi I, Sudoyo AW, Sumadibrata M, Setiyohadi B, Syam AF. Buku Ajar Ilmu Penyakit Dalam. 6th ed. Jakarta: Interna Publishing; 2014.
Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, γglutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care. 2009;32(4):741–50.
Oikonomou D, Georgiopoulos G, Katsi V, Kourek C, Tsioufis C, Alexopoulou A, et al. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated? Eur J Gastroenterol Hepatol. 2018;30(9):979–85.
López-Suárez A, Guerrero JMR, Elvira-González J, Beltrán-Robles M, Cañas-Hormigo F, Bascuñana-Quirell A. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur J Gastroenterol Hepatol. 2011;23(11):1011–7.
Fahim SM, Chowdhury MAB, Alam S. Non-alcoholic fatty liver disease (NAFLD) among underweight adults. Clin Nutr ESPEN. 2020;38:80–5.
Kiapidou S, Liava C, Kalogirou M, Akriviadis E, Sinakos E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know? Ann Hepatol. 2020;19(2):134–44.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
